Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.5K
Coagulation01:09

Coagulation

9.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.4K
Coagulation01:06

Coagulation

1.1K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

228
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptive graph learning of microbial phylogeny enables accurate and interpretable microbiome-based host phenotype prediction.

Applied and environmental microbiology·2026
Same author

Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION).

European urology·2026
Same author

Telerobotic partial nephrectomy and radical prostatectomy using a hybrid network: A single-center prospective experience.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Clinical Outcomes of Orchiopexy and the Risk of Malignancy in Postpubertal Cryptorchid Patients.

Andrology·2026
Same author

Size-dependent ruthenium/ceria nanozymes synchronize catalytic ROS scavenging and electrostatic mtDNA sequestration for periodontitis therapy.

Journal of nanobiotechnology·2026
Same author

Bi-A@SR Nanoparticles Enable Tumor-Localized NO Release to Suppress HSP70 and Reverse Chemoresistance.

Advanced healthcare materials·2026

Related Experiment Video

Updated: Dec 28, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII.

Jenni Firrman1,2, Qizhao Wang3, Wenman Wu3

  • 1Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA, USA.

Molecular Therapy. Methods & Clinical Development
|February 20, 2020
PubMed
Summary

Canine factor VIII light chain enhances human factor VIII activity. Researchers identified 12 specific amino acids responsible for this enhancement, creating a new variant with improved in vitro and in vivo coagulation activity for potential hemophilia A therapies.

Keywords:
FVIII proteincoagulation factor VIIIfactor VIIIgenetic engineeringhemophilia A

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.1K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K

Related Experiment Videos

Last Updated: Dec 28, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.1K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Hematology

Background:

  • Canine factor VIII (cFVIII) exhibits higher specific activity than human FVIII (hFVIII).
  • The light chain of cFVIII has been shown to enhance hFVIII activity.

Purpose of the Study:

  • Identify specific amino acids in the cFVIII light chain responsible for enhancing hFVIII activity.
  • Develop a novel hFVIII variant with improved functional activity using identified amino acids.

Main Methods:

  • Systematic screening of human-canine light chain hybrids.
  • Individual screening of canine amino acids within a key span (1857-2147) using negative selection.
  • Substitution of identified amino acids into hFVIII to create the hFVIIIJF12BDD variant.

Main Results:

  • Identified a 12-amino acid sequence (JF12) in the cFVIII light chain crucial for activity enhancement.
  • The hFVIIIJF12BDD variant demonstrated elevated specific activity in vitro.
  • hFVIIIJF12BDD showed increased in vivo coagulation activity compared to wild-type hFVIII, with normal secretion efficiency.

Conclusions:

  • Pinpointed key amino acids in cFVIII responsible for its higher specific activity.
  • The identified amino acids and the developed hFVIIIJF12BDD variant offer a promising basis for future hemophilia A therapeutic development.